Imbalance Between CD44 and STAT3 Enhances Spheroid Viability and Impairs Pembrolizumab Response in Urothelial Cancer

KEITA GOTO; KIYOHIRO ANDO; NORIKO MOTOI; TOSHIHIKO IIZUKA; HIROTAKA FUCHIZAWA; YUKI NAKAMURA; YUTA SANO; SHOTARO MATSUOKA; HISANORI TAKENOBU; MASAYUKI HARUTA; RITSUKO ONUKI; YOH MATSUOKA; TAKEHIKO KAMIJO; YUKIO KAGEYAMA

doi:10.21873/anticanres.18129

Research ArticleExperimental Studies

Imbalance Between CD44 and STAT3 Enhances Spheroid Viability and Impairs Pembrolizumab Response in Urothelial Cancer

KEITA GOTO, KIYOHIRO ANDO, NORIKO MOTOI, TOSHIHIKO IIZUKA, HIROTAKA FUCHIZAWA, YUKI NAKAMURA, YUTA SANO, SHOTARO MATSUOKA, HISANORI TAKENOBU, MASAYUKI HARUTA, RITSUKO ONUKI, YOH MATSUOKA, TAKEHIKO KAMIJO and YUKIO KAGEYAMA

Anticancer Research May 2026, 46 (5) 2445-2453; DOI: https://doi.org/10.21873/anticanres.18129

KEITA GOTO

1Department of Urology, Saitama Cancer Center, Saitama, Japan;

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

KIYOHIRO ANDO

2Research Institute for Clinical Oncology, Saitama Cancer Center, Saitama, Japan;

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site
For correspondence: kiyohiro_ando{at}saitama-pho.jp

NORIKO MOTOI

3Department of Pathology, Saitama Cancer Center, Saitama, Japan;

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

TOSHIHIKO IIZUKA

3Department of Pathology, Saitama Cancer Center, Saitama, Japan;

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

HIROTAKA FUCHIZAWA

1Department of Urology, Saitama Cancer Center, Saitama, Japan;

4Department of Urology, Dokkyo Medical University, Tochigi, Japan

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

YUKI NAKAMURA

1Department of Urology, Saitama Cancer Center, Saitama, Japan;

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

YUTA SANO

1Department of Urology, Saitama Cancer Center, Saitama, Japan;

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

SHOTARO MATSUOKA

1Department of Urology, Saitama Cancer Center, Saitama, Japan;

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

HISANORI TAKENOBU

2Research Institute for Clinical Oncology, Saitama Cancer Center, Saitama, Japan;

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

MASAYUKI HARUTA

2Research Institute for Clinical Oncology, Saitama Cancer Center, Saitama, Japan;

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

RITSUKO ONUKI

2Research Institute for Clinical Oncology, Saitama Cancer Center, Saitama, Japan;

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

YOH MATSUOKA

1Department of Urology, Saitama Cancer Center, Saitama, Japan;

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

TAKEHIKO KAMIJO

2Research Institute for Clinical Oncology, Saitama Cancer Center, Saitama, Japan;

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

YUKIO KAGEYAMA

1Department of Urology, Saitama Cancer Center, Saitama, Japan;

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Article
Figures & Data
Info & Metrics
PDF

This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.

Log in using your username and password

Username *

Password *

Forgot your user name or password?

Purchase access

You may purchase access to this article. This will require you to create an account if you don't already have one.

patientACCESS

patientACCESS - Patients desiring access to articles

PreviousNext

In this issue

Anticancer Research

Vol. 46, Issue 5

May 2026

Table of Contents
Table of Contents (PDF)
About the Cover
Index by author
Ed Board (PDF)

Download PDF

Article Alerts

User Name *

Password *

Email *

Email Article

Thank you for your interest in spreading the word on Anticancer Research.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Your Email *

Your Name *

Send To *

Enter multiple addresses on separate lines or separate them with commas.

You are going to email the following Imbalance Between CD44 and STAT3 Enhances Spheroid Viability and Impairs Pembrolizumab Response in Urothelial Cancer

Message Subject (Your Name) has sent you a message from Anticancer Research

Message Body (Your Name) thought you would like to see the Anticancer Research web site.

Your Personal Message

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Math question * 12 + 6 =

Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.

Citation Tools

Imbalance Between CD44 and STAT3 Enhances Spheroid Viability and Impairs Pembrolizumab Response in Urothelial Cancer

Anticancer Research May 2026, 46 (5) 2445-2453; DOI: 10.21873/anticanres.18129

Citation Manager Formats

BibTeX
Bookends
EasyBib
EndNote (tagged)
EndNote 8 (xml)
Medlars
Mendeley
Papers
RefWorks Tagged
Ref Manager
RIS
Zotero

Reprints and Permissions

Imbalance Between CD44 and STAT3 Enhances Spheroid Viability and Impairs Pembrolizumab Response in Urothelial Cancer

Anticancer Research May 2026, 46 (5) 2445-2453; DOI: 10.21873/anticanres.18129

Share This Article:

Tweet Widget
Facebook Like
Google Plus One

Jump to section

Article
Figures & Data
Info & Metrics
PDF

Cited By...

No citing articles found.

Google Scholar

Keywords

pembrolizumab
Urothelial carcinoma
CD44
STAT3

Main menu

User menu

Search

Imbalance Between CD44 and STAT3 Enhances Spheroid Viability and Impairs Pembrolizumab Response in Urothelial Cancer

Purchase access

patientACCESS

In this issue

Citation Manager Formats

Related Articles

Cited By...

More in this TOC Section

Keywords